MX9702244A - Derivado de 1,2,3,4-tetrahidroquinoxalinadiona. - Google Patents
Derivado de 1,2,3,4-tetrahidroquinoxalinadiona.Info
- Publication number
- MX9702244A MX9702244A MX9702244A MX9702244A MX9702244A MX 9702244 A MX9702244 A MX 9702244A MX 9702244 A MX9702244 A MX 9702244A MX 9702244 A MX9702244 A MX 9702244A MX 9702244 A MX9702244 A MX 9702244A
- Authority
- MX
- Mexico
- Prior art keywords
- amino
- carboxy
- lower alkyl
- substituted
- halogeno
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un derivado de 1,2,3,4-tetrahidroquinoxalinadiona representado por la siguiente formula (I) o sal del mismo, un receptor de NMDA, glicina y/o antagonista de receptor de AMPA o inhibidor de neurotoxicidad de ácido caínico que contiene el derivado o sal. Además, una composicion farmacéutica que comprende dicho compuesto y un vehículo farmacéuticamente aceptable (Ver Formula) en donde los símbolos de la formula anterior representan respectivamente los siguientes significados: X: N, CH, R: un grupo imidazolilo o un grupo dialquilamino inferior, R1: (1) un átomo de halogeno, un grupo nitro, un grupo ciano, un grupo carboxilo, un grupo amino, un grupo mono o dialquilamino inferior, un grupo alcanoilo inferior, un grupo alquiltio inferior, un grupo alquilsulfinilo inferior, un grupo alquilsulfonilo inferior o un grupo carbamoilo; (2) un grupo alquilo inferior o un grupo alcoxilo inferior que se puede substituir por un átomo de halogeno, un grupo carboxilo o un grupo arilo; (3) un grupo feniloxi que se puede substituir por un grupo alcoxicarbonilo inferior o un grupo carboxilo; R2 representa un grupo hidroxilo, un grupo alcoxi inferior, un grupo amino o un grupo mono o dialquilamino inferior; A: un grupo alquileno inferior que puede estar substituido o un grupo representado por la formula -O-B-, y B: un grupo alquileno inferior, con la condicion de que se excluye el caso en donde R, representa un grupo imidazolino, R1 representa ciano, A representa un grupo etileno y R2 representa un grupo hidroxilo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23190894 | 1994-09-27 | ||
JP5948295 | 1995-03-17 | ||
PCT/JP1995/001922 WO1996010023A1 (fr) | 1994-09-27 | 1995-09-25 | Derive de 1,2,3,4-tetrahydroquinoxalindione |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9702244A true MX9702244A (es) | 1997-06-28 |
Family
ID=26400527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9702244A MX9702244A (es) | 1994-09-27 | 1995-09-25 | Derivado de 1,2,3,4-tetrahidroquinoxalinadiona. |
Country Status (16)
Country | Link |
---|---|
US (1) | US6096743A (es) |
EP (1) | EP0784054B1 (es) |
KR (1) | KR100392151B1 (es) |
CN (1) | CN1067387C (es) |
AT (1) | ATE209644T1 (es) |
CA (1) | CA2199468C (es) |
DE (1) | DE69524246T2 (es) |
DK (1) | DK0784054T3 (es) |
ES (1) | ES2168383T3 (es) |
HU (1) | HU223945B1 (es) |
MX (1) | MX9702244A (es) |
PL (1) | PL181532B1 (es) |
PT (1) | PT784054E (es) |
RU (1) | RU2149873C1 (es) |
UA (1) | UA44283C2 (es) |
WO (1) | WO1996010023A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057304A (en) * | 1992-10-26 | 2000-05-02 | Schering Aktiengesellschaft | Quinoxaline-phosphonic acid derivatives |
DE19519979A1 (de) * | 1995-05-24 | 1996-11-28 | Schering Ag | Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln |
TW448171B (en) * | 1996-06-06 | 2001-08-01 | Yamanouchi Pharma Co Ltd | Imidazole-substituted quinoxalinedione derivatives |
AU6310498A (en) * | 1997-03-14 | 1998-10-12 | Meiji Seika Kaisha Ltd. | Physiologically active substance pf1191 and process for producing the same |
DE19728326A1 (de) * | 1997-06-27 | 1999-01-07 | Schering Ag | Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln |
IL139783A0 (en) * | 1998-06-01 | 2002-02-10 | Shionogi & Co | Cyanoiminoquinoxaline derivates |
ATE324369T1 (de) | 1999-02-15 | 2006-05-15 | Eisai Co Ltd | Heterodiazinon-derivate |
US6790978B2 (en) | 1999-03-29 | 2004-09-14 | Novartis Ag | Thyromimetic organic compounds |
US6599942B1 (en) | 1999-03-29 | 2003-07-29 | Novartis Ag | Thyromimetic organic compounds |
US6709667B1 (en) | 1999-08-23 | 2004-03-23 | Conceptus, Inc. | Deployment actuation system for intrafallopian contraception |
WO2001055110A1 (en) * | 2000-01-24 | 2001-08-02 | Neurosearch A/S | Isatine derivatives with neurotrophic activity |
US6949571B2 (en) | 2000-06-12 | 2005-09-27 | Eisai Co., Ltd. | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
PT1522590E (pt) * | 2000-06-28 | 2009-10-26 | Glycofi Inc | Métodos para a produção de glicoproteínas modificadas |
AU2002250256B2 (en) * | 2001-03-08 | 2008-04-03 | Emory University | pH-dependent NMDA receptor antagonists |
GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
AU2003220825A1 (en) * | 2002-03-29 | 2003-10-13 | Yamanouchi Pharmaceutical Co., Ltd. | Remedy for glioblastoma |
CA2482937A1 (en) * | 2002-04-17 | 2003-10-23 | Yamanouchi Pharmaceutical Co., Ltd. | A novel crystal of anhydride of a quinoxalinedione derivative |
WO2004002488A1 (ja) * | 2002-06-28 | 2004-01-08 | Yamanouchi Pharmaceutical Co., Ltd. | 脳出血治療剤 |
US20040152694A1 (en) * | 2003-02-04 | 2004-08-05 | Istvan Kurucz | Methods and compositions for treating inflammatory disorders of the airways |
GB0405034D0 (en) * | 2004-03-05 | 2004-04-07 | Novartis Ag | Organic compounds |
MY148809A (en) | 2004-07-06 | 2013-05-31 | Eisai R&D Man Co Ltd | Crystals of 1,2-dihydropyridine compound and their production process |
ME01224B (me) * | 2005-04-04 | 2013-06-20 | Eisai R&D Man Co Ltd | Jedinjenja dihidropiridina za liječenje neurodegenerativnih bolesti i demencije |
WO2007020521A1 (en) * | 2005-08-16 | 2007-02-22 | Pharmacia & Upjohn Company Llc | Pyridoyrazinones as pde-5 inhibitors |
RU2498980C2 (ru) * | 2007-05-29 | 2013-11-20 | Сантен Фармасьютикал Ко., Лтд. | Новое производное 1,2,3,4-тетрагидрохиноксалина, содержащее в качестве заместителя фенильную группу, имеющую структуру эфира сульфокислоты или амида сульфокислоты, и обладающее связывающей активностью в отношении рецептора глюкокортикоидов |
US8420680B2 (en) | 2007-06-29 | 2013-04-16 | Emory University | NMDA receptor antagonists for neuroprotection |
US20100113461A1 (en) | 2008-10-29 | 2010-05-06 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds |
WO2010074807A1 (en) | 2008-10-30 | 2010-07-01 | Gilead Palo Alto, Inc. | 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators |
EP2338492A1 (en) * | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
WO2020124090A1 (en) | 2018-12-14 | 2020-06-18 | Eisai R&D Management Co., Ltd. | Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds |
JPWO2023042888A1 (es) | 2021-09-15 | 2023-03-23 | ||
JPWO2023042887A1 (es) | 2021-09-15 | 2023-03-23 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU656154B2 (en) * | 1990-11-06 | 1995-01-27 | Astellas Pharma Inc. | Fused pyrazine derivative |
PT101004B (pt) * | 1991-10-26 | 1999-10-29 | Schering Ag | Derivados da quinoxalina, processo para a sua preparacao e composicoes farmaceuticas que os contem |
IL109397A0 (en) * | 1993-04-28 | 1994-07-31 | Schering Ag | Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
JPH07165756A (ja) * | 1993-12-14 | 1995-06-27 | Yamanouchi Pharmaceut Co Ltd | ヒドロキシキノキサリンジオン誘導体 |
US5654303A (en) * | 1995-06-07 | 1997-08-05 | Warner-Lambert Company | Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
-
1995
- 1995-09-25 HU HU9702043A patent/HU223945B1/hu not_active IP Right Cessation
- 1995-09-25 UA UA97031348A patent/UA44283C2/uk unknown
- 1995-09-25 AT AT95932217T patent/ATE209644T1/de not_active IP Right Cessation
- 1995-09-25 EP EP95932217A patent/EP0784054B1/en not_active Expired - Lifetime
- 1995-09-25 PT PT95932217T patent/PT784054E/pt unknown
- 1995-09-25 CA CA002199468A patent/CA2199468C/en not_active Expired - Fee Related
- 1995-09-25 RU RU97104870/04A patent/RU2149873C1/ru not_active IP Right Cessation
- 1995-09-25 CN CN95195237A patent/CN1067387C/zh not_active Expired - Fee Related
- 1995-09-25 WO PCT/JP1995/001922 patent/WO1996010023A1/ja active IP Right Grant
- 1995-09-25 PL PL95320059A patent/PL181532B1/pl not_active IP Right Cessation
- 1995-09-25 DK DK95932217T patent/DK0784054T3/da active
- 1995-09-25 US US08/809,087 patent/US6096743A/en not_active Expired - Fee Related
- 1995-09-25 KR KR1019970701879A patent/KR100392151B1/ko not_active IP Right Cessation
- 1995-09-25 ES ES95932217T patent/ES2168383T3/es not_active Expired - Lifetime
- 1995-09-25 DE DE69524246T patent/DE69524246T2/de not_active Expired - Fee Related
- 1995-09-25 MX MX9702244A patent/MX9702244A/es not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PT784054E (pt) | 2002-05-31 |
CA2199468A1 (en) | 1996-04-04 |
EP0784054A1 (en) | 1997-07-16 |
HU223945B1 (hu) | 2005-03-29 |
UA44283C2 (uk) | 2002-02-15 |
KR100392151B1 (ko) | 2003-11-20 |
HUT77442A (hu) | 1998-04-28 |
EP0784054A4 (en) | 1998-01-07 |
ATE209644T1 (de) | 2001-12-15 |
CN1067387C (zh) | 2001-06-20 |
WO1996010023A1 (fr) | 1996-04-04 |
US6096743A (en) | 2000-08-01 |
EP0784054B1 (en) | 2001-11-28 |
DE69524246D1 (de) | 2002-01-10 |
AU3533795A (en) | 1996-04-19 |
PL320059A1 (en) | 1997-09-01 |
CA2199468C (en) | 2006-06-06 |
DK0784054T3 (da) | 2002-03-25 |
CN1168670A (zh) | 1997-12-24 |
KR970706274A (ko) | 1997-11-03 |
AU684392B2 (en) | 1997-12-11 |
ES2168383T3 (es) | 2002-06-16 |
DE69524246T2 (de) | 2002-06-27 |
RU2149873C1 (ru) | 2000-05-27 |
PL181532B1 (pl) | 2001-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9702244A (es) | Derivado de 1,2,3,4-tetrahidroquinoxalinadiona. | |
EP0992239A4 (en) | NEUROPEPTIDE Y RECEPTOR ANTAGONIST | |
MX9606510A (es) | Derivados benzoheterociclicos. | |
IL142649A0 (en) | Azole derivatives | |
WO2001009103A3 (en) | Imidazole antiproliferative agents | |
AP9801312A0 (en) | 4-aminopyrrole (3,2-d) pyrimidines as neuropeptide y receptor anatagonist. | |
FI954746A (fi) | Urea- ja amidijohdannaisia ja niiden käyttö solukalvojen kaliumkanavien säätelyyn | |
GR3034542T3 (en) | 4,5-diaryloxazole derivatives | |
AP9801321A0 (en) | 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-h-indole derivatives. | |
WO2001036425A3 (de) | Imidazolverbindungen als phosphodiesterase vii-hemmer | |
BG104447A (en) | Biphenylamidine derivatives | |
JO2065B1 (en) | Tri-azin compounds | |
IL148548A0 (en) | Bicyclic vasopressin agonists | |
CA2244621A1 (en) | 4-aminopyrrole (3,2-d) pyrimidines as neuropeptide y receptor antagonists | |
GC0000218A (en) | New imidazole derivatives | |
EP0919554A4 (en) | CHINOXALINDION DERIVATIVES SUBSTITUTED BY IMIDAZOLE | |
ES2103222A1 (es) | Derivados tioalquiltiocarbacefalosporina. | |
RS50449B (sr) | Supstituisani bisindolilmaleimidi za inhibiciju proliferacije ćelija | |
IE832664L (en) | Penems. | |
MX9605794A (es) | Intermediario para preparar un compuesto farmaceuticamente activo. | |
AU653019B2 (en) | New urea derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | |
TW247909B (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
HC | Change of company name or juridical status |
Owner name: BGREEN LIMITED |
|
MM | Annulment or lapse due to non-payment of fees |